Date:10/27/2011

ed these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 25, 2011, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

PERRIGO COMPANYCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands)(unaudited)First Quarter20122011Cash Flows (For) From Operating Activities   Net income

$

70,458$

74,375   Adjustments to derive cash flows Gain on sale of pipeline research and development projects(3,500)-Depreciation and amortization34,72023,436Share-based compensation3,9353,682Income tax benefit from exercise of stock options2,1251,941Excess tax benefit of stock transactions(10,578)(9,465)Deferred income taxes(3,084)(59,069)   Subtotal94,07634,900   Changes in operating assets and liabilities, net of business acquisitionAccounts receivable8,581(58,401)Inventories(7,156)(3,559)Accounts payable(47,249)(9,636)Payroll and related taxes(10,681)(21,191)Accrued customer programs(5,708)11,201Accrued liabilities17,678(12,899)Accrued income taxes(878)49,152Other5,4844,271   Subtotal(39,929)(41,062)
'/>"/>

SOURCE Perrigo Company Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related medicine technology :

1. Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solution
2. Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel
3. Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350
4. Perrigo Confirms Filing for Generic Version of Mens Rogaine(R) Foam
5. Perrigo Company Will Release First Quarter Fiscal 2010 Results on November 2, 2009
6. Perrigo Company Announces Dividend Increase
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Company Will Release Second Quarter Fiscal 2010 Results on February 2, 2010
9. Perrigo Company to Present at the 28th Annual J.P. Morgan Healthcare Conference
10. Perrigo Company To Present at the Sidoti Emerging Growth Conference
11. Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix